Actinogen Medical Limited (ATGGF)

OTCMKTS · Delayed Price · Currency is USD
0.0200
0.00 (0.00%)
Nov 29, 2024, 4:00 PM EST
33.33%
Market Cap 55.15M
Revenue (ttm) 6.63M
Net Income (ttm) -8.70M
Shares Out n/a
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open 0.0200
Previous Close 0.0200
Day's Range 0.0200 - 0.0200
52-Week Range 0.0150 - 0.0200
Beta 1.74
Analysts n/a
Price Target n/a
Earnings Date Nov 24, 2024

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol ATGGF
Full Company Profile

Financial Performance

In 2024, Actinogen Medical's revenue was 9.93 million, an increase of 103.18% compared to the previous year's 4.89 million. Losses were -13.04 million, 21.3% more than in 2023.

Financial numbers in AUD Financial Statements

News

There is no news available yet.